Stimulant Oxytocin Study

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

January 26, 2018

Primary Completion Date

February 14, 2020

Study Completion Date

February 14, 2020

Conditions
Stimulant Use & Co-occuring Opioid Use Disorders
Interventions
DRUG

Intranasal oxytocin

Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a oxytocin nasal spray 40 International Units (IU) to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.

DRUG

Intranasal placebo

Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a placebo nasal spray 40IU to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.

Trial Locations (3)

94121

San Francisco VA Medical Center, San Francisco, CA, San Francisco

95655

VA Northern California Health Care System, Mather, CA, Sacramento

97239

VA Portland Health Care System, Portland, OR, Portland

All Listed Sponsors
lead

VA Office of Research and Development

FED

NCT03016598 - Stimulant Oxytocin Study | Biotech Hunter | Biotech Hunter